Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 119

Sort by

Sort Order Select

Journal Articles

Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Blood blood.2025031313.

https://doi.org/10.1182/blood.2025031313

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis

Blood (2025) 146 (Supplement 1): 2516.

https://doi.org/10.1182/blood-2025-2516

Published: 2025

Journal Articles

Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia

Brian Jonas, Sangeetha Venugopal, George Yaghmour, Manu Pandey, Anthony Selwyn Stein, Mikkael Sekeres, Namrata Chandhok, Rasmus Hoeg, Joseph Tuscano, Pamela Becker, Terrence Bradley, Eric Tam, Guido Marcucci, Paul Frankel, Jan Beumer, Steven Gore, Alexey Danilov, Amandeep Salhotra

Blood (2025) 146 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2025-1651

Published: 2025

Journal Articles

Total marrow and lymphoid irradiation (TMLI) with fludarabine-melphalan (FM) conditioning for matched donor hematopoietic cell transplant (HCT) in older patients with Relapsed/Refractory (R/R) disease

Monzr M. Al Malki, Susanta Hui, Dongyun Yang, Sally Mokhtari, Hoda Pourhassan, Matthew Mei, Amanda Blackmon, Firoozeh Sahebi, Amandeep Salhotra, Brian Ball, Shukaib Arslan, Salman Otoukesh, Haris Ali, Guido Marcucci, Ryotaro Nakamura, Stephen Forman, Anthony Selwyn Stein, Jeffrey Wong

Blood (2025) 146 (Supplement 1): 376.

https://doi.org/10.1182/blood-2025-376

Published: 2025

Journal Articles

Axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease: Interim safety analysis of a phase 2, randomized study

Robert Zeiser, Annie Im, Albert Assad, Maureen Bleam, Hongfei Li, Amandeep Salhotra

Blood (2025) 146 (Supplement 1): 6012.

https://doi.org/10.1182/blood-2025-6012

Published: 2025

Journal Articles

Long-term treatment duration and safety of axatilimab among patients with chronic graft-versus-host disease in AGAVE-201

Carrie Kitko, Amandeep Salhotra, Mi Kwon, Zhenyi Xue, Valkal Bhatt, John Galvin, Patrick Hardesty, Silvia Mosher, Daniel Wolff

Blood (2025) 146 (Supplement 1): 6010.

https://doi.org/10.1182/blood-2025-6010

Published: 2025

Journal Articles

Computed tomography quantification of body adiposity and induction outcomes in patients with newly diagnosed acute lymphoblastic leukemia

Jose Tinajero, Hoda Pourhassan, Chandana Lall, Dat Ngo, Vaibhav Agrawal, Paul Koller, Lindsey Murphy, Shukaib Arslan, Yazeed Samara, Amandeep Salhotra, Stephen Forman, Guido Marcucci, Anthony Selwyn Stein, Ibrahim Aldoss, Vinod Pullarkat

Blood (2025) 146 (Supplement 1): 6829.

https://doi.org/10.1182/blood-2025-6829

Published: 2025

Journal Articles

High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL): primary analysis of a Phase 1/2 study

Blood (2025) 146 (Supplement 1): 3352.

https://doi.org/10.1182/blood-2025-3352

Published: 2025

Journal Articles

Clearance of RAS pathway mutations prior to allogeneic transplant in Acute Myeloid Leukemia are associated with favorable overall and leukemia free survival

Blood (2025) 146 (Supplement 1): 4305.

https://doi.org/10.1182/blood-2025-4305

Published: 2025

Journal Articles

First-in-human phase I trial combining radiopharmaceutical therapy (RPT) using a 90y-anti-CD25 monoclonal antibody (Mab) with total marrow and lymphoid irradiation (TMLI) in relapsed or refractory (R/R) acute leukemia

Blood (2025) 146 (Supplement 1): 508.

https://doi.org/10.1182/blood-2025-508

Published: 2025

Journal Articles

Total marrow and lymphoid irradiation (2000 cGy) together with cyclophosphamide and etoposide prior to allogeneic hematopoietic cell transplantation is an effective regimen for Relapsed/Refractory leukemia, with low non-relapse mortality

Blood (2025) 146 (Supplement 1): 2441.

https://doi.org/10.1182/blood-2025-2441

Published: 2025

Journal Articles

The addition of venetoclax to FLAG IDA or FCE in relapsed or refractory (R/R) acute myeloid leukemia (AML)

Blood (2025) 146 (Supplement 1): 1684.

https://doi.org/10.1182/blood-2025-1684

Published: 2025

Journal Articles

Post-transplant cyclophosphamide-based graft-verses-host disease (GVHD) prophylaxis is associated with a low incidence of fibrotic chronic GVHD after allogeneic hematopoietic cell transplantation across diverse donor types

Klara Kim, Dat Ngo, Jose Tinajero, Dongyun Yang, Haoyue Shan, Karamjeet Sandhu, Haris Ali, Salman Otoukesh, Idoroenyi Amanam, Shukaib Arslan, Vaibhav Agrawal, Sunmin Park, Ryotaro Nakamura, Monzr M. Al Malki, Amandeep Salhotra

Blood (2025) 146 (Supplement 1): 935.

https://doi.org/10.1182/blood-2025-935

Published: 2025

Journal Articles

Preliminary safety and efficacy of myeloablative orca-q with tacrolimus or without graft-versus-host disease prophylaxis for treatment of advanced hematologic malignancies

Samer Srour, Mehrdad Abedi, Amandeep Salhotra, Edmund Waller, Hannah Choe, Anna Pavlova, Tamara Zharkevich, Scott Killian, J. Scott McClellan, Nate Fernhoff, Robert Lowsky

Blood (2025) 146 (Supplement 1): 932.

https://doi.org/10.1182/blood-2025-932

Published: 2025

Journal Articles

Intensive chemotherapy bridging to allogeneic hematopoietic cell transplant in relapsed or refractory Acute Myeloid Leukemia

Paul Koller, Jose Tinajero, Dat Ngo, Dongyun Yang, Ahmed Aribi, Ibrahim Aldoss, Vinod Pullarkat, Amandeep Salhotra, Eileen Smith, Anthony Selwyn Stein, Guido Marcucci, Stephen Forman, Ryotaro Nakamura, Monzr M. Al Malki

Blood (2025) 146 (Supplement 1): 3411.

https://doi.org/10.1182/blood-2025-3411

Published: 2025

Journal Articles

Day 7 mount sinai acute GVHD international consortium (MAGIC) algorithm probability predicts GVHD and non-GVHD-related non-relapse mortality in a contemporary cohort of allogeneic transplant patients

Blood (2025) 146 (Supplement 1): 2464.

https://doi.org/10.1182/blood-2025-2464

Published: 2025

Journal Articles

The MEASURE Genome Atlas: Acute Myeloid Leukemia at diagnosis and complete remission

Kai Yu, Laura Dillon, Jesse Tettero, Gege Gui, Rasha Al-Ali, Michael Grunwald, Elizabeth Krakow, Elizabeth Griffiths, Alexandra Gomez-Arteaga, Rahul Vedula, Melhem Solh, Amandeep Salhotra, Nelli Bejanyan, Lori Muffly, Antonio Jimenez-Jimenez, Michael Drazer, Yi-Bin Chen, Aaron Logan, Reena Jayani-Kosarzycki, Sophia Balderman, James Blachly, Brian Shaffer, Marc Schwartz, Cecilia Yeung, Lawrence Druhan, Vanessa Kennedy, Sandeep Gurbuxani, Melissa Tjota, Max Smith, Farah Sahoo, Dylan Barfield, Jim Guo, James Han, Jason Hu, Heejoon Jo, Vidya Kudlingar, Wilfred Li, Yutong Qiu, Pratheesh Sathyan, Sean Truong, Severine Catreux, Sam Ng, Khai Luong, Yunjiao Zhu, Reem Bahr, Jamie Diemer, Jianqun Kou, Stephanie Bo-Subait, Jackie Bjerke, Steven Devine, Bergetta Dietel, Christina Ferrone, Gabrielle Giammarino, Emily Heying, Emily Kolb, Danielle O'Donnell Vitali, Wael Saber, Stephen Spellman, Brenna Tesch, Jenny Vogel, Stephanie Waldvogel, Syreeta Weatherspoon, Jeffery Auletta, Christopher Hourigan

Blood (2025) 146 (Supplement 1): 455.

https://doi.org/10.1182/blood-2025-455

Published: 2025

Journal Articles

CD19-CAR T cell therapy as a definitive consolidation in older adults with b-ALL in CR1 is safe and induces durable MRD- remission

Blood (2025) 146 (Supplement 1): 443.

https://doi.org/10.1182/blood-2025-443

Published: 2025

Journal Articles

First-in-human trial of allogeneic CD6-CAR tregs in patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation

Amandeep Salhotra, Jamie Wagner, Dongyun Yang, Haris Ali, Salman Otoukesh, Jemily Juan, Sindhu Saraswathy, Isaac Garcia, Dileshni Tilakawardane, Sunmin Park, Stephen Forman, Ryotaro Nakamura, Christine Brown, Enrique Montero

Blood (2025) 146 (Supplement 1): 276.

https://doi.org/10.1182/blood-2025-276

Published: 2025

Journal Articles

Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial

Blood (2025) 146 (Supplement 1): 2477.

https://doi.org/10.1182/blood-2025-2477

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis

Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia

Total marrow and lymphoid irradiation (TMLI) with fludarabine-melphalan (FM) conditioning for matched donor hematopoietic cell transplant (HCT) in older patients with Relapsed/Refractory (R/R) disease

Axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease: Interim safety analysis of a phase 2, randomized study

Long-term treatment duration and safety of axatilimab among patients with chronic graft-versus-host disease in AGAVE-201

Computed tomography quantification of body adiposity and induction outcomes in patients with newly diagnosed acute lymphoblastic leukemia

High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL): primary analysis of a Phase 1/2 study

Clearance of RAS pathway mutations prior to allogeneic transplant in Acute Myeloid Leukemia are associated with favorable overall and leukemia free survival

First-in-human phase I trial combining radiopharmaceutical therapy (RPT) using a 90y-anti-CD25 monoclonal antibody (Mab) with total marrow and lymphoid irradiation (TMLI) in relapsed or refractory (R/R) acute leukemia

Total marrow and lymphoid irradiation (2000 cGy) together with cyclophosphamide and etoposide prior to allogeneic hematopoietic cell transplantation is an effective regimen for Relapsed/Refractory leukemia, with low non-relapse mortality

The addition of venetoclax to FLAG IDA or FCE in relapsed or refractory (R/R) acute myeloid leukemia (AML)

Post-transplant cyclophosphamide-based graft-verses-host disease (GVHD) prophylaxis is associated with a low incidence of fibrotic chronic GVHD after allogeneic hematopoietic cell transplantation across diverse donor types

Preliminary safety and efficacy of myeloablative orca-q with tacrolimus or without graft-versus-host disease prophylaxis for treatment of advanced hematologic malignancies

Intensive chemotherapy bridging to allogeneic hematopoietic cell transplant in relapsed or refractory Acute Myeloid Leukemia

Day 7 mount sinai acute GVHD international consortium (MAGIC) algorithm probability predicts GVHD and non-GVHD-related non-relapse mortality in a contemporary cohort of allogeneic transplant patients

The MEASURE Genome Atlas: Acute Myeloid Leukemia at diagnosis and complete remission

CD19-CAR T cell therapy as a definitive consolidation in older adults with b-ALL in CR1 is safe and induces durable MRD- remission

First-in-human trial of allogeneic CD6-CAR tregs in patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation

Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only